Spero Therapeutics (SPRO) Enterprise Value (2016 - 2026)
Spero Therapeutics posted quarterly Enterprise Value of -$56.1 million for Q1 2026, down 14.81% year-on-year from -$65.9 million in Q1 2025, and down 39.4% on a QoQ basis from -$40.3 million in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of Enterprise Value data on file, last reported at -$56.1 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 14.81% year-over-year to -$56.1 million; the trailing twelve-month figure through Mar 2026 stood at -$56.1 million (down 14.81% YoY), and the FY2025 full-year result was -$40.3 million, up 23.87% from the prior year.
- Enterprise Value for Q1 2026 stood at -$56.1 million, down from -$40.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$31.2 million in Q2 2025 and bottomed at -$122.0 million in Q1 2022.
- The 5-year median for Enterprise Value is -$63.5 million (2024), against an average of -$68.9 million.
- The widest annual swing landed in 2022, when Enterprise Value surged 59.13%; it then slumped 85.99% in 2023.
- A 5-year view of Enterprise Value shows it stood at -$109.1 million in 2022, then jumped by 30.04% to -$76.3 million in 2023, then surged by 30.71% to -$52.9 million in 2024, then rose by 23.87% to -$40.3 million in 2025, then sank by 39.4% to -$56.1 million in 2026.
- The last three Enterprise Value figures came in at -$56.1 million (Q1 2026), -$40.3 million (Q4 2025), and -$48.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | -56.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.13 Mn |
| Dec 31, 2025 | -40.27 Mn |
| Sep 30, 2025 | -48.62 Mn |
| Jun 30, 2025 | -31.19 Mn |
| Mar 31, 2025 | -48.89 Mn |
| Dec 31, 2024 | -52.89 Mn |
| Sep 30, 2024 | -76.29 Mn |
| Jun 30, 2024 | -63.53 Mn |
| Mar 31, 2024 | -82.27 Mn |
| Dec 31, 2023 | -76.33 Mn |
| Sep 30, 2023 | -93.83 Mn |
| Jun 30, 2023 | -77.69 Mn |
| Mar 31, 2023 | -96.25 Mn |
| Dec 31, 2022 | -109.11 Mn |
| Sep 30, 2022 | -50.45 Mn |
| Jun 30, 2022 | -45.40 Mn |
| Mar 31, 2022 | -121.97 Mn |
| Dec 31, 2021 | -146.40 Mn |
| Sep 30, 2021 | -123.42 Mn |
| Jun 30, 2021 | -99.22 Mn |
| Mar 31, 2021 | -115.68 Mn |
| Dec 31, 2020 | -126.91 Mn |
| Sep 30, 2020 | -127.24 Mn |
| Jun 30, 2020 | -71.36 Mn |
| Mar 31, 2020 | -88.84 Mn |
| Dec 31, 2019 | -82.05 Mn |
| Sep 30, 2019 | -93.50 Mn |
| Jun 30, 2019 | -103.05 Mn |
| Mar 31, 2019 | -106.04 Mn |
| Dec 31, 2018 | -115.09 Mn |
| Sep 30, 2018 | -130.87 Mn |
| Jun 30, 2018 | -66.28 Mn |
| Mar 31, 2018 | -75.04 Mn |
| Dec 31, 2017 | -86.93 Mn |
| Sep 30, 2017 | -25.01 Mn |
| Jun 30, 2017 | 6.40 Mn |
| Dec 31, 2016 | -14.12 Mn |
| Sep 30, 2016 | -11.28 Mn |